3260 Bayshore Boulevard
About CareDx, Inc.
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit: www.caredx.com.
127 articles with CareDx, Inc.
New Data on AlloSure Confirms Its Clinical Utility in Repeat Kidney Transplant Recipients Study published in the American Journal of Transplantation
CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces the publication of data demonstrating the clinical utility of measuring AlloSure in repeat kidney transplant recipients in the American Journal of Transplantation.
CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $24.50 per share.
CareDx symposium and panel presentations will showcase AlloSure experience.
Innovative AlloSure registry brings standardization to transplant centers.
The company reported preliminary financial results for the fourth quarter and full year ended December 31, 2017.
This confirms that the AlloMap reimbursement rate will be increased to $3,240.
The company reported that it has agreed to immediately repay certain obligations related to CareDx’s acquisition of Allenex AB, which eliminates the requirement to issue 1.8 million new shares.
Achieved total revenue for the third quarter of 2017 of $12.2 million.
Eight new employees were awarded grants of options to purchase CareDx common stock under NASDAQ Listing Rule 5635(c)(4).
The CEO and CFO will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.
CareDx Describes Extensive Analytical Validation Data On AlloSure Robustness At American Association Of Clinical Chemistry Annual Meeting